|
|||||
|
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone |
|
| Authors: | T. Forst R. Guthrie R. Goldenberg J. Yee U. Vijapurkar G. Meininger P. Stein |
| Affiliation: | 1. Profil Mainz, , Mainz, Germany;2. Johannes Gutenberg University, , Mainz, Germany;3. The Ohio State University, , Columbus, OH, USA;4. LMC Diabetes & Endocrinology, , Thornhill, Ontario, Canada;5. Janssen Research & Development, LLC, , Raritan, NJ, USA |
| Abstract: | |
| Keywords: | metformin phase 3 study SGLT2 inhibitor thiazolidinediones type 2 diabetes |